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tion was noted between the PAI-1 gene polymorphism and thePlasminogen activator inhibitor-1 gene polymorphism 4G/4G
chronicity of the nephritis.genotype and lupus nephritis in Chinese patients.
Conclusion. These findings suggest that the 4G/5G polymor-Background. Abnormal regulation in the coagulation and
phism of the PAI-1 gene is associated with the activity but notfibrinolytic system may play an important role in mediating
the chronicity of lupus nephritis. The presence of the 4G4Gglomerular damage in lupus nephritis. Indeed, glomerular
genotype does not increase the risk of developing SLE or lupusthrombosis occurs frequently in lupus nephritis and predicts
nephritis, but predicts the development of higher nephritisthe future development of glomerular sclerosis. In the murine
activity and more extensive necrotizing lesions.model of active lupus nephritis, plasminogen activator inhibi-
tor-1 (PAI-1) gene was overexpressed throughout the kidney,
both within the glomeruli and also in tubules and vessels. The
level of PAI-1 expression in the tissues appeared to correlate
Systemic lupus erythematosus (SLE) is a chronic in-with the progression of lupus nephritis. Recently, a single base
flammatory disease with multiorgan involvement, wherepair insertion/deletion 4G/5G polymorphism of the PAI-1 gene
has been identified and shown to alter plasma PAI-1 activity. up to 70% of patients with SLE develop lupus nephritis
This study was therefore conducted to determine the associa- [1]. The disease is multifactorial, with both environmen-
tion of the 4G/5G polymorphism of the PAI-1 gene with the tal and genetic factors implicated. Although the geneticdevelopment and severity of lupus nephritis.
basis of SLE is not fully understood, there is emergingMethods. The PAI-1 gene polymorphism of 118 systemic
evidence that certain human lymphocyte antigen (HLA)lupus erythematosus (SLE) patients and 103 healthy controls
who were gender and age matched was determined using stan- and non-HLA alleles predispose to the development of
dard polymerase chain reaction. PAI-1 genotype results were SLE and lupus nephritis. For instance, SLE patients with
studied in relationship to the development and severity of lupus DR2 and DQw1 positivity have low levels of tumor ne-nephritis.
crosis factor-a (TNF-a) inducibility and are associatedResults. Allele frequencies of 4G/5G allele were 0.59/0.41
with the development of lupus nephritis, while the DR3in lupus patients and 0.59/0.41 in controls (P 5 1.000). No
significant difference was noted in the genotype distribution and DR4 haplotypes are associated with high TNF-a
between SLE patients with and without nephritis. However, production and are negatively correlated with lupus ne-
lupus nephritis patients with the 4G4G genotype showed sig-
phritis [2]. The non-major histocompatibility complexnificantly heavier proteinuria (5.0 vs. 3.7 g/day; P 5 0.023)
(MHC)-linked gene such as the IgG Fc receptor IIa poly-when compared with patients with 4G5G and 5G5G genotypes.
Also, 73.3% patients with 4G4G had an activity index $8 morphism [3] has also been shown to be associated with
versus 37.3% patients with 4G5G and 5G5G (P 5 0.003). the development and severity of lupus nephritis. The
Extensive necrotizing lesions were seen in 51.7% patients with associations of different MHC and non-MHC genes with
4G4G as compared with 23.5% patients with 4G5G and 5G5G
the development and severity of lupus nephritis suggest(P 5 0.014). The association of the 4G4G gene polymorphism
that the disease is strongly genetically predisposed.with a higher nephritis activity and more severe necrotizing
lesions persisted when only class III and class IV nephritis Endothelial cell activation and proliferation with sub-
patients were studied. On the other hand, no significant associa- sequent intravascular coagulation and fibrin deposition
in the glomeruli are well-recognized features of active
lupus nephritis [4–6]. Dysregulation in the coagulationKey words: PAI-1 genotypes, fibrinolysis, glomerular injury, glomeru-
losclerosis, systemic lupus nephritis, necrotizing lesions. and fibrinolytic system causes persistent fibrin deposition
in the intraglomerular capillaries [7] and may promoteReceived for publication March 3, 2000
further glomerular injury by causing capillary thrombosisand in revised form October 18, 2000
Accepted for publication November 6, 2000 and subsequent inflammatory cell infiltration. Glomeru-
lar fibrin deposit also has direct cytotoxic effect on mes-Ó 2001 by the International Society of Nephrology
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angial cells [8]. Recent studies indicate that endothelial structive uropathy were excluded. Case records of all
patients were reviewed, and clinical information was re-cells play an important role in fibrinolysis by secreting
both tissue-plasminogen activator (t-PA), which con- trieved from the case records. The information retrieved
included clinical manifestation, organ involvement, pres-verts plasminogen to plasmin, and plasminogen activator
inhibitor-1 (PAI-1), which regulates the activity of t-PA. ence of hypertension, initial renal function and protein-
uria before initiation of imunosuppressive treatment,Endothelial cells produce large amount of PAI-1 in re-
sponse to interleukin-1 (IL-1), TNF, and lipopolysaccha- treatment received, duration of follow-up, latest renal
function, and history of renal relapse. Renal relapse isride (LPS) stimulation. Increased PAI-1 expression in
the glomerulus inhibits fibrin clearance at sites of coagu- defined as clinical evidence of relapse of lupus nephritis
activity, namely rising proteinuria or serum creatininelation and causes disease progression. Keeton et al dem-
onstrated that female MRL/lpr mice developing early- with dropping complement levels with or without con-
firmation by renal biopsy and requiring stepping up oronset lupus nephritis with fibrin deposition show increased
PAI-1 expression throughout the kidney, within both the addition of immunosuppressive therapy.
the glomeruli, tubules, and vessels, while normal kidney
Renal biopsy reviewshowed no detectable level of PAI-1 [9]. Moreover, the
level of PAI-1 expression is correlated with the severity Lupus nephritis was classified according to World Health
Organization (WHO) classification [15]: class I, normalof lupus nephritis [9], suggesting that this important
inhibitor of fibrinolysis may indeed contribute to the glomeruli; class II, mesangial alterations (lupus mesangi-
opathy); class III, focal segmental glomerulonephritispathogenesis and progression of lupus nephritis.
Recently, a single base pair guanosine insertion/dele- (with active necrotizing lesions and/or sclerosis); class IV,
diffuse proliferative glomerulonephritis (with or withouttion polymorphism has been identified in the promoter
region of the PAI-1 gene, situated 675 bp upstream from segmental lesions); and class V, diffuse membranous glo-
merulonephritis. Specific histologic features were usedthe start of transcription [10, 11], and shown to alter
PAI-1 gene expression in response to acute phase stimu- to assess the severity of lupus nephritis, and a previously
reported semiquantitative scoring system was used tolus or cytokine stimulation such as IL-1 and TNF through
an altered affinity for an nuclear factor-kB (NF-kB)-like grade individual biopsy features as described later in this
article [16]. The scoring system used a scale of 0, 1, 2,factor [12]. The insertion/deletion 4G/5G polymorphism
has been shown to alter circulating PAI-1 activity in or 3 corresponding to absent, mild (in less than 25% of
glomeruli), moderate (affecting 25 t o 50% of glomeruli),healthy individuals [12], in non–insulin-dependent diabe-
tes mellitus (NIDDM) patients [13], and in patients with or severe (affecting more than 50% of glomeruli), respec-
tively, for each individual histologic feature. The firstcoronary heart disease [14]. Patients with the 4G4G ge-
notype have the highest levels of PAI-1 activity, while renal biopsy of all nephritis patients before embarking
on any immunosuppressive treatment was used for his-those with 5G5G genotype have the lowest plasma PAI-1
activity [12–14]. Therefore, our study investigated the tology review. The presence of six or more glomeruli
was considered adequate for biopsy grading. Two pathol-effect of this single base pair insertion/deletion 4G/5G
polymorphism of the PAI-1 gene on the development and ogists graded the biopsies independently without knowl-
edge of the patients’ clinical history, renal function, andseverity of lupus nephritis. It also examined the effect of
this polymorphism on the progression of lupus nephritis. PAI-1 genotype. The average of the scores graded by
the two pathologists was taken as the final score.
Activity index. The activity index was defined as the
METHODS
sum of individual scores of the following features consid-
Patient selection ered to represent measures of active lupus nephritis:
endocapillary hypercellularity (score 0 to 3), cellularOne hundred eighteen patients who fulfilled the Amer-
ican College of Rheumatology (ACR) Classification of crescent (score 0, 2, 4, 6), necrotizing lesion (score 0, 2, 4,
6), hyaline deposit and thrombi (score 0 to 3), interstitialSLE were recruited from the Prince of Wales Hospital
in Hong Kong, and 103 healthy subjects were recruited inflammatory cells (score 0 to 3), and glomerular leuko-
cytes (score 0 to 3). The maximum score was 24 pointsas controls. All study subjects, including SLE patients
and healthy controls, were of Southern Chinese origin. for the activity index.
Chronicity index. This index consisted of the sum ofSLE patients were divided into two groups, namely those
with renal involvement (LN1) and those without renal the following features considered to represent measures
of chronic irreversible lupus lesions: glomerular sclerosisinvolvement (LN2). Renal involvement was defined ac-
cording to ACR criteria, namely, persistent proteinuria (score 0 to 3), fibrous crescents (score 0 to 3), tubular
atrophy (score 0 to 3), and interstitial fibrosis (score 0 to.0.5 g/day or 31 proteinuria on urine dipsticks with
or without the presence of cellular casts. Patients with 3). The maximum score was 12 points for the chronicity
index.diabetes mellitus, other coexisting renal disease, or ob-
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Table 1. Comparison of the sex and age distribution, plasminogen
activator inhibitor-1 (PAI-1) genotype distribution and allele
frequency of 118 systemic lupus nephritis (SLE) patients and
103 healthy controls
SLE Control
(N5118) (N5103) P value
Male:female 11:107 10:93 NS
Median (IQR) age 37 (28–43) 35 (28–42) NS
PAI-1 genotype
4G/4G 42 (35.6) 37 (35.9) NS
4G/5G 56 (47.5) 48 (46.6)
5G/5G 20 (16.9) 18 (17.5)
Allele frequency
4G 0.59 0.59 NS
5G 0.41 0.41
Categorical variables are given as N (%). IQR is interquartile range.
rated by gel electrophoresis in 2% agarose gel (GIBCO,
Grand Island, NY, USA), which had been stained with
ethidium bromide and viewed under ultraviolet irradia-
tion. Each subject was classified into 4G4G, 4G5G, or
5G5G according to the presence of the 139 bp PCR
product generated by the allele-specific primers (Fig. 1).
Statistical analysisFig. 1. Determining PAI-1 gene polymorphism using insertion 5G (top
panel) and deletion 4G (bottom panel) allele-specific primers with a Continuous variables were expressed as median [inter-
common downstream primer in a separate PCR reaction. Results of quartile range (IQR)]. Differences in continuous vari-six patients are shown as examples (lane 1–6). Lane 1–5, G5G; Lane
ables between LN1 and LN2 patients between 4G4G2, 4, and 5, 4G5G; Lane 3 and 6, 4G4G; Lane M, ØX174 marker; pc,
positive control. and 4G5G/5G5G genotypes were compared using the
Mann–Whitney test. Chi-square analysis was used to
compare the PAI-1 genotype distribution between SLE
patients and healthy controls, and between LN1 andDetermination of PAI-1 4G/5G genotype
LN2 patients. Chi-square analysis was also used to com-
Genomic DNA was extracted from peripheral blood pare the PAI-1 genotype distribution in relationship to
leukocytes of all 118 SLE patients and 103 healthy con- the specific histologic grading of the severity of lupus
trols by standard techniques. PAI-1 4G/5G promoter ge- nephritis. Interobserver concordance of the different his-
notype polymorphism was determined by polymerase tologic features was assessed using k value. Correlation
chain reaction (PCR) amplification of genomic DNA of between proteinuria, activity index and chronicity intex
all subjects using the allele specific primers, (1) insertion was tested using Spearman correlation. A level of P ,
5G allele 59-GTC TGG ACA CGT GGG GG-39 and (2) 0.05 was considered statistically significant.
deletion 4G allele 59-GTC TGG ACA CGT GGG GA-39.
Each in combination with a common downstream primer,
RESULTS59-TGC AGC CAG CCA CGT GAT TGT CTA G-39,
PAI-1 gene polymorphism in SLE patients andgave rise to a 139 base pair DNA fragment. A control
healthy controlsupstream primer, 59-AAG CTT TTA CCA TGG TAA
CCC CTG GT-39, was used as a positive control in the Table 1 shows the PAI-1 genotype distribution and the
PCR [17]. allele frequency in 118 SLE patients (107 female and 11
The 25 mL PCR mixture contained 50 pmol allele male) and 103 controls (93 female and 10 male). The
specific primer, 50 pmol common downstream primer, mean age was comparable between the SLE patients and
2.5 pmol control upstream primer, 1 3 PCR buffer, healthy controls. In both SLE patients and controls, the
2.0 mmol/L magnesium chloride, 0.2 mmol/L dNTPs, and observed distribution of homozygotes and heterozygotes
1.25 U Taq polymerase. All the reagents required for conformed to expectations based on the Hardy–Wein-
PCR were purchased from Boehringer Mannheim (Mann- berg equilibrium analysis. No significant difference was
heim, Germany). The thermal cycling conditions were noted in the PAI-1 genotype distribution of SLE patients
948C for 45 seconds, 678C for 45 seconds, and 728C for versus controls (4G4G:4G5G:5G5G 5 35.6:47.5:16.9%
SLE vs. 35.9:46.6:17.5% controls; P 5 NS). Allele fre-75 seconds for 30 cycles. The PCR products were sepa-
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Table 2. Clinical features and genotype distribution of SLE patients with nephritis (LN1) and without nephritis (LN2)
LN1 patients LN2 patients
(N593) (N520) P value
Female/male 84/9 18/2 NS
Age of onset of SLE years 26 (19–34) 27 (20–36) NS
Duration of follow-up months 92 (48–139) 73 (45–109) NS
ARC score 6 (5–8) 6 (5–6) NS
With hypertension % 51.1 5.0 0.0001
PAI-1 genotype
4G4G 34 (36.6) 6 (30.0)
4G5G 42 (45.1) 13 (65.0) NS
5G5G 17 (18.3) 1 (5.0)
Continuous variables are given as median (interquartile range, IQR) and categorical variables as N (%). ARC is American College of Rheumatology.
Table 3. PAI-1 genotype distribution of patients with differentquency of 4G/5G allele was 0.59/0.41 in lupus patients
WHO classes of lupus nephritis
and 0.59/0.41 in controls (P 5 NS).
WHO class
Distribution of PAI-1 gene polymorphism in LN1 Overall III IV V
and LN2 patients PAI-1 genotype (N591) (N519) (N554) (N518) P value
4G4G 34 (37.3) 5 (26.3) 22 (40.7) 7 (38.9)Details of renal involvement were not available in 5
4G5G 41 (46.2) 12 (63.2) 22 (40.7) 7 (38.9) NSaout of 118 patients. Of the remaining 113 patients, 93
5G5G 16 (18.7) 2 (10.5) 10 (18.5) 4 (22.2)
(82%) had lupus nephritis, while 20 (18%) did not have
Genotypes are given as N (%).lupus nephritis. Of the 93 patients with lupus nephritis, a Comparison of genotype distribution among class III, IV and V nephritis
patients2 (2%) had class II, 19 (21%) had class III, 54 (58%)
had class IV, and 18 (19%) had class V lupus nephritis,
classified according to WHO classification. The baseline
characteristics of the LN1 and LN2 patients are shown
(N 5 59) genotypes are shown in Table 4. No significantin Table 2. No significant difference was noted in the
difference was noted in the gender distribution, age ofsex distribution and age of onset of SLE between patients
onset of SLE, ACR score at initial presentation, and thewith and without lupus nephritis. The median duration
duration of follow-up between patients of the 4G4G andof follow-up was 92 (48–139) months for those with lupus
4G5G/5G5G genotypes. Patients of the 4G4G genotypenephritis versus 73 (45–109) months for those without
had significantly higher proteinuria (Uprot) on initial pre-lupus nephritis (P 5 NS). No significant difference was
sentation as compared with those of 4G5G/5G5G geno-noted in the PAI-1 4G/5G genotype distribution between
types [median (IQR) baseline Uprot g/day, 4G4G 5 5.0LN1 (N 5 93) and LN2 (N 5 20) patients (4G4G:
(2.9–7.6) vs. 4G5G/5G5G 5 3.7 (1.7–5.4), P 5 0.023;4G5G:5G5G 5 36.6:45.1:18.3% LN1 vs. 30.0:65.0:5.0%
Table 4]. No significant difference, however, was notedLN2; P 5 NS; Table 2). However, LN1 patients had a
in the baseline serum creatinine (SCr) [4G4G 5 91significantly higher incidence of hypertension (51.1 vs.
(62–179) mmol/L vs. 4G5G/5G5G 5 90 (68–120) mmol/L,5.0%, P 5 0.0001) and more frequent use of angiotensin-
P 5 NS] and creatinine clearance (CCr) [4G4G 5 67converting enzyme inhibitor (ACEI; 42.6 vs. 0%; P 5
(40–93) mL/min vs. 4G5G/5G5G 5 66 (45–83) mL/min,0.0001) as compared with LN patients. Moreover, a sig-
P 5 NS] between patients of the 4G4G and 4G5G/5G5Gnificant difference was noted in the choice of immuno-
genotypes. The 4G4G:4G5G:5G5G genotype distribu-suppressive treatment between LN1 and LN2 patients.
tion was 30.8:46.2:23.0% for patients with baseline SCr ,Potent immunosuppressive treatment, including cyclo-
130 mmol/L as compared with 52.2:43.5:4.3% for patientsphosphamide and cyclosporine with or without azathio-
with baseline SCr $130 mmol/L (P 5 0.066). No significantprine, was used in 92.5% of LN1 patients as compared
difference was noted in the incidence of hypertensionwith 0% of LN2 patients (P 5 0.0001). The PAI-1 geno-
between patients with the 4G4G (52.9%) and 4G5G/type distribution, however, showed no significant differ-
5G5G genotypes (50.8%) (P 5 NS). The type of immu-ence among the different WHO classes of lupus nephritis
nosuppressive treatment received was also comparable(4G4G:4G5G:5G5G 5 26.3:63.2:10.5% class III vs. 40.7:
among patients of the 4G4G versus 4G5G/5G5G geno-40.7:18.5% class IV vs. 38.9:38.9:22.2% class V; P 5 NS;
type (Table 4). However, a significantly greater propor-Table 3).
tion of patients of the 4G4G genotype (61.8%) were
Lupus nephritis and PAI-1 gene polymorphism treated with ACEI as compared with patients of 4G5G/
5G5G genotypes (30.5%, P 5 0.005). During the dura-The clinical and biochemical features of patients with
lupus nephritis with 4G4G (N 5 34) versus 4G5G/5G5G tion of follow-up, 73.5% patients with the 4G4G versus
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Table 4. Comparison of clinical and biochemical characteristics of lupus nephritis patients with the 4G4G versus 4G5G/5G5G genotypes
4G4G 4G5G/5G5G
(N534) (N559) P value
Female/male 32/2 52/7 NS
Age of onset of SLE years 27 (19–35) 25 (19–33) NS
ACR score at presentation 6 (5–8) 6 (5–7) NS
Baseline Uprot g/day 5.0 (2.9–7.6) 3.7 (1.7–5.4) 0.023
Baseline SCr lmol/L 91 (62–179) 95 (68–120) NS
Baseline CCr mL/min 67 (40–93) 66 (45–83) NS
Activity index on baseline biopsy 10 (5–13) 7 (4–9) 0.033
Chronicity index on baseline biopsy 2 (0–4) 2 (0–3) NS
Duration of follow-up months 92 (47–132) 91 (48–139) NS
With hypertension % 52.9 50.8 NS
Treated with ACEI % 61.8 30.5 0.005
Treated with dipyridamole % 8.8 8.5 NS
Immunosuppressive therapy received %
Prednisolone only 0 3.4
Prednisolone6azathioprine 5.9 5.1
Cyclosporine6azathioprine 35.3 33.9 NS
Cyclophosphamide6azathioprine 29.4 23.7
Cyclosporine 1 cyclophosphamide 29.4 33.9
With renal flare % 73.5 67.8 NS
SCr at the latest follow-up lmol/L 89 (69–140) 91 (67–164) NS
CCr at the latest follow-up mL/min 61 (36–89) 60 (32–79) NS
Categorical variables are given as N (%) and continuous variables as median (interquartile range, IQR). Abbreviations are: SLE, systemic lupus nephritis; ACR,
American College of Rheumatology; Uprot, proteinuria; SCr, serum creatinine; CCr, creatinine clearance; ACEI, angiotensin-converting enzyme inhibitor.
67.8% patients with the 4G5G/5G5G genotype had a 0.001). The degree of proteinuria also showed a signifi-
renal relapse (P 5 NS). cant correlation with activity index (r 5 0.514, P , 0.001)
Renal biopsies of 81 patients (4G4G, N 5 30; 4G5G, and chronicity index (r 5 0.372, P , 0.001) for the entire
N 5 36; 5G5G, N 5 15) with underlying lupus nephritis group of patients.
were available for histology review. The remaining 12 Specific histologic features of lupus nephritis used to
patients either had initial biopsies performed in other score activity index and chronicity index were compared
hospitals or the biopsies were considered inadequate for between patients of 4G4G and 4G5G/5G5G genotypes
histologic grading of disease activity. The activity index (Table 5). There was no significant difference in the
of each individual patient was plotted in a dot column degree of hypercellularity, hyaline deposit, glomerular
format, grouped according to the PAI-1 genotype (Fig. leukocytes, and interstitial inflammatory cell infiltration
2A). Overall, the activity index of patients with the 4G4G between nephritis patients with the 4G4G and 4G5G/
genotype was significantly higher compared with those 5G5G genotypes. However, 30% patients with the 4G4G
with 4G5G/5G5G genotypes [median (IQR) activity in- genotype had $25% cellular crescents formation as com-
dex, 4G4G vs. 4G5G/5G5G 5 10 (5–13) vs. 7 (4–9), P 5
pared with 13.5% patients with the 4G5G/5G5G geno-
0.033; Table 4]. No significant difference, however, was
types (P 5 0.086; Table 5). More important, patients of
noted in the chronicity index between patients with
the 4G4G genotype showed more extensive necrotizing4G4G and 4G5G/5G5G genotypes [median (IQR) CI,
lesions as compared with patients of the 4G5G/5G5G4G4G vs. 4G5G/5G5G 5 2 (0–4) vs. 2 (0–3), P 5 NS;
genotypes; necrotizing lesions were present in at leastTable 4]. The activity index was $8 in 73.3% patients
$25% of glomeruli in 51.7% patients with 4G4G versuswith the 4G4G as compared with 37.3% patients with
23.5% patients with 4G5G/5G5G genotype (P 5 0.014;the 4G5G/5G5G genotypes (P 5 0.003; Table 5). The
Table 5). On the other hand, the degree of glomerulo-chronicity index was $4 in 26.7% patients with the 4G4G
sclerosis, fibrous crescents, tubular atrophy, and intersti-genotype as compared with 23.5% patients with the
tial fibrosis showed no significant difference between4G5G/5G5G genotype (P 5 NS; Table 5).
patients of the 4G4G and 4G5G/5G5G genotypes. TheThe activity index was plotted against the chronicity
association of 4G4G gene polymorphism with higherindex for each individual according to the PAI-1 geno-
nephritis activity [median (IQR) activity index, 4G4Gtype result (Fig. 2B). A significant correlation was noted
vs. 4G5G/5G5G 5 10 (9–14) vs. 7 (6–11); P 5 0.001] andbetween activity index and chronicity index for patients
more extensive necrotizing lesions (necrotizing lesions inwith the 4G4G genotype (r 5 0.66, P , 0.001) and
patients with the 4G5G/5G5G genotype (r 5 0.48, P , $25% of the glomeruli, 4G4G vs. 4G5G/5G5G 5 68.2%
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Fig. 2. (A) AI of nephritis plotted for each individual patient, grouped according to the PAI-1 genotype using a dot column format. (B) Scatter
plot showing activity index of each individual patient in relationship to chronicity index according to the PAI-1 genotype.
vs. 30.8%; P 5 0.007) persisted when only class III and pathologists were 0.863, 0.934, 0.950, 0.842, 0.914, 0.786,
class IV nephritis patients were studied. 0.936, 0.882, 0.828, and 0.754, respectively, all of statisti-
The k values used to assess interobserver concordance cal significance with P , 0.001.
of the different histologic features including endocapil-
lary hypercellularity, cellular crescent, necrotizing lesion,
DISCUSSIONhyaline deposit, interstitial inflammatory cells, glomeru-
lar leukocytes, glomerular sclerosis, fibrous crescents, This study describes a novel association between the
PAI-1 4G/5G gene polymorphism and lupus nephritis.tubular atrophy, and interstitial fibrosis between the two
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Table 5. Comparison of specific histologic features of lupus amined in relationship to the PAI-1 4G/5G genotype. It
nephritis patients with the 4G4G and 4G5G/5G5G genotypes
was noted that the PAI-1 gene polymorphism was
4G4G 4G5G/5G5G strongly associated with the degree of necrotizing lesions
Features (N530) (N551) P value in lupus nephritis; patients of the 4G4G genotype showed
Activity index more extensive necrotizing lesions when compared with
,8 8 (26.7) 32 (62.7) 0.003
those of the 4G5G or 5G5G genotype. Only a very weak$8 22 (73.3) 19 (37.3)
Chronicity index association was noted between the PAI-1 polymorphism
,4 22 (73.3) 39 (76.5) and the formation of cellular crescents. No significant
$4 8 (26.7) 12 (23.5) NS
association was noted between the PAI-1 gene polymor-Endocapillary hypercellularity
0–1 17 (56.7) 27 (52.9) phism and other active histologic features including en-
2–3 13 (43.3) 24 (47.1) NS docapillary hypercellularity, interstitial inflammatory
Cellular crescenta
cell infiltration, glomerular leukocytes, and hyaline de-0–2 21 (70.0) 45 (86.5)
4–6 9 (30.0) 7 (13.5) 0.086 posits. This suggests that the PAI-1 gene polymorphism
Necrotizing lesiona is important in mediating the activity of lupus nephritis
0–2 14 (48.3) 39 (76.5)
and may be specifically associated with the development4–6 15 (51.7) 12 (23.5) 0.014
Hyaline deposit and thrombi of necrotizing lesions.
0–1 19 (63.3) 40 (78.4) Previous studies have shown that intravascular throm-
2–3 11 (36.7) 11 (21.6) 0.196
bosis is a characteristic feature of lupus nephritis and isGlomerular leukocytes
0–1 25 (83.3) 47 (92.2) associated with the development of more severe histo-
2–3 5 (16.7) 4 (7.8) NS logic features, including necrosis and endocapillary pro-
Interstitial inflammatory cells
liferation [5]. Glomerular thrombosis also has been shown0–1 24 (80) 44 (86.3)
2–3 6 (20) 7 (13.7) NS to be an important predictor of subsequent glomerulo-
Glomerulosclerosis sclerosis [5]. The exact cause of glomerular thrombosis
0–1 27 (90.0) 42 (82.4) NS
in lupus nephritis remains unknown, but dysregulation2–3 3 (10.0) 9 (17.6)
Fibrous crescents of the coagulation and fibrinolytic pathway may be one
0–1 30 (100) 49 (96.1) possible mechanism. In fact, fibrinolytic abnormalities
2–3 0 (0) 2 (3.9) NS
with elevated PAI-1 levels have been demonstrated inTubular atrophy
0–1 26 (86.7) 41 (80.4) a significant proportion of SLE patients [6, 18, 19]. PAI-1
2–3 4 (13.3) 10 (19.6) NS inhibits both urokinase and t-PA and controls the rate
Interstitial fibrosis
of plasmin generation from plasminogen. Overexpres-0–1 28 (93.3) 42 (82.4)
2–3 2 (6.7) 9 (17.6) NS sion of PAI-1 results in an imbalance between plasmino-
gen/plasmin systems. This, in turn, causes persistent fi-Categorial variables are given as N (%). Scale 0–1 is absent-mild, and 2–3 is
moderate-severe. brin deposition in the intraglomerular capillaries and
a Scale 0–2 is absent-mild, and 4–6 is moderate-severe.
promotes further glomerular injury by causing capillary
thrombosis with subsequent inflammatory cell infiltra-
tion [7]. There is evidence to suggest that dysregulation
of the coagulation and fibrinolytic system may be impor-Lupus nephritis patients of the 4G4G genotype showed
significantly heavier proteinuria and a higher activity tant mediators of glomerular injury in lupus nephritis
[20, 21]. Indeed, studies in the murine model of lupusindex than those of the 4G5G or 5G5G genotype. A
significantly greater proportion of patients with the nephritis showed overexpression of the PAI-1 gene
throughout the kidney, both within the glomeruli and in4G4G genotype had an activity index score of $8 rather
than ,8. Indeed, a significant correlation was also noted tubules and vessels, while no detectable expression was
noted in the normal kidney [9]. In addition, a decreasebetween the degree of proteinuria and activity index of
the nephritis. The association between the 4G4G geno- in t-PA expression is demonstrated. These changes cor-
relate not only with the development of lupus nephritistype and greater nephritis activity was even stronger
when only class III and IV nephritis patients were stud- but also with the glomerular fibrin deposition in the
murine nephritic kidney [22–24]. Moreover, the levelied. However, no significant difference was noted in the
genotype distribution and allele frequency between SLE of PAI-1 expression appears to be correlated with the
severity of the disease [9]. Taken together, these observa-patients and controls, or between patients with and with-
out nephritis, or among patients with the different WHO tions suggest that overexpression of the PAI-1 gene pro-
motes the formation of microthrombi and contributes toclasses of lupus nephritis. There was also no association
of the PAI-1 gene polymorphism with the chronicity of the progression of lupus nephritis.
However, the exact role of PAI-1 in the formation ofthe nephritis.
Moreover, individual histologic features used to score necrotizing lesions remains to be determined. Although
endothelial cells produce a large amount of PAI-1, stud-the activity index and chronicity index were further ex-
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ies showed that mice with LN showed high levels of type may be reflected by more severe proteinuria in
PAI-1 mRNA at many sites of active disease, including patients of the 4G4G as compared with those of the
endothelial cells in the glomerulus, glomerular crescents, 4G5G/5G5G genotypes. No association was noted, how-
and glomerular and tubular epithelial cells [9]. We postu- ever, between the PAI-1 gene polymorphism and chro-
late that enhanced PAI-1 expression in the endothelial nicity of the nephritis or the susceptibility to renal flares.
cells may be responsible for suppressing the fibrinolytic We conclude that dysregulation in the coagulation and
system locally within the renal vasculature, hence causing fibrinolytic pathway is important in mediating the activ-
intravascular coagulation associated with lupus nephritis ity of lupus nephritis, and may be related to the underly-
and necrotizing lesions. Studies of lupus nephritis in ing PAI-1 4G/5G genetic polymorphism. Further studies
MRL/lpr mice showed that other cytokines, including are needed to determine the role of PAI-1 in the develop-
TNF [25, 26] and transforming growth factor (TGF) [27], ment of necrotizing lesions in the human model of lupus
which induce PAI-1 gene expression, may account for nephritis.
the more widespread expression of PAI-1 in other renal
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